ReviewDrugs2008
Mosapride in gastrointestinal disorders.
Review in Drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.Drugs in R&D · 2017Pooled it
- Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: a systematic review.World journal of gastroenterology · 2013Pooled it
- Effects of prucalopride succinate on postoperative bowel motility and inflammation following minimally invasive gastrectomy.Scientific reports · 2026Trial
- Mosapride versus Metoclopramide in Critically Ill Patients with Enteral Feeding Intolerance: A Randomized, Double-Blinded Comparison.Drug design, development and therapy · 2026Trial
- Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial.Gut and liver · 2018Trial
- Effect of mosapride citrate on gastric emptying in interferon-induced gastroparesis.Digestive diseases and sciences · 2012Trial
- Mosapride promotes internalization of a TREK1-HTR4 complex and exerts rapid antidepressant-like effects.Molecular psychiatry · 2026Article
- Evolving prokinetic therapy: New targets and therapeutic opportunities in gastrointestinal motility disorders.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- The efficacy of mosapride on recovery of intestinal motility after elective colorectal cancer surgery: a randomized controlled trial.Annals of coloproctology · 2025Article
- Olive Oil Solution of Volatile Oil fromDrug design, development and therapy · 2025Article
- Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases.International journal of molecular sciences · 2024Review
- Mosapride stimulates human 5-HTNaunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Clinical Trial: Efficacy of Mosapride Controlled-release and Nortriptyline in Patients With Functional Dyspepsia: A Multicenter, Double-placebo, Double-blinded, Randomized Controlled, Parallel Clinical Study.Journal of neurogastroenterology and motility · 2024Article
- Randomized Controlled Trial Comparing the Efficacy of Sustained-Release Formula of Mosapride-Plus-Esomeprazole Combination Therapy to Esomeprazole Monotherapy in Patients with Gastroesophageal Reflux Disease.Journal of clinical medicine · 2022Article
- Improved motility in the gastrointestinal tract of a postoperative ileus rat model with ilaprazole.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2021Article
- Article
- International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.Pharmacological reviews · 2021Review
- Article
- Radiofrequency catheter ablation-induced gastroparesis successfully treated with administration of mosapride citrate: two case reports.Clinical journal of gastroenterology · 2020Article
- Paeoniflorin Alleviates Abnormalities in Rats with Functional Dyspepsia by Stimulating the Release of Acetylcholine.Drug design, development and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mosapride was effective in improving overall symptoms in patients with gastrointestinal disorders, including chronic gastritis, gastro-oesophageal reflux disease and functional dyspepsia. Mosapride was more effective than teprenone in improving gastric stasis symptoms and gastric pain after 2 weeks of therapy (p < 0.001) in an open-label trial in 1042 patients with functional dyspepsia. Mosapride was as effective as famotidine and itopride, but more effective than tandospirone, in improving overall or individual symptoms of functional dyspepsia in randomized trials. However, in one randomized, double-blind trial in patients with mild to severe disease, the improvement in overall symptoms of functional dyspepsia did not differ significantly between mosapride or placebo treatment. Mosapride was well tolerated, with diarrhoea/loose stools, dry mouth, malaise and headache being reported in <5% of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.